Terms: = Lung cancer AND KMT2D, ENSG00000167548, 8085, MLL2 AND Treatment
67 results:
1. Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell lung cancer.
Abdullah S; Chakraborty R; Kumkar PS; Debnath B; Bala A
J Environ Pathol Toxicol Oncol; 2024; 43(3):13-38. PubMed ID: 38608143
[TBL] [Abstract] [Full Text] [Related]
2. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
Xin Y; Liu CG; Zang D; Chen J
Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
[TBL] [Abstract] [Full Text] [Related]
3. A cisplatin and disulphiram co-loaded inclusion complex overcomes drug resistance by inhibiting cancer cell stemness in non-small cell lung cancer.
Ye W; Lv H; Zhang Q; Zhao J; Zhao X; Zhao G; Yan C; Sun F; Zhao Z; Jia X
J Drug Target; 2024 Dec; 32(2):159-171. PubMed ID: 38133515
[No Abstract] [Full Text] [Related]
4. Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in lung cancer.
Geng P; Zhao J; Li Q; Wang X; Qin W; Wang T; Shi X; Liu X; Chen J; Qiu H; Xu G
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069368
[TBL] [Abstract] [Full Text] [Related]
5. Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.
Zhang L; Wang Y; Wang L; Wang M; Li S; He J; Ji J; Li K; Cao L
J Mol Med (Berl); 2024 Jan; 102(1):69-79. PubMed ID: 37978056
[TBL] [Abstract] [Full Text] [Related]
6. Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.
Tuli HS; Garg VK; Choudhary R; Iqubal A; Sak K; Saini AK; Saini RV; Vashishth K; Dhama K; Mohapatra RK; Gupta DS; Kaur G
Mol Biol Rep; 2023 Mar; 50(3):2685-2700. PubMed ID: 36534236
[TBL] [Abstract] [Full Text] [Related]
7. kmt2d deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
Pan Y; Han H; Hu H; Wang H; Song Y; Hao Y; Tong X; Patel AS; Misirlioglu S; Tang S; Huang HY; Geng K; Chen T; Karatza A; Sherman F; Labbe KE; Yang F; Chafitz A; Peng C; Guo C; Moreira AL; Velcheti V; Lau SCM; Sui P; Chen H; Diehl JA; Rustgi AK; Bass AJ; Poirier JT; Zhang X; Ji H; Zhang H; Wong KK
Cancer Cell; 2023 Jan; 41(1):88-105.e8. PubMed ID: 36525973
[TBL] [Abstract] [Full Text] [Related]
8. Interaction of MRPL9 and GGCT Promotes Cell Proliferation and Migration by Activating the MAPK/ERK Pathway in Papillary Thyroid cancer.
Zhang HM; Li ZY; Dai ZT; Wang J; Li LW; Zong QB; Li JP; Zhang TC; Liao XH
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233293
[TBL] [Abstract] [Full Text] [Related]
9. Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant lung cancer.
Xin Q; Ji Q; Zhang Y; Ma W; Tian B; Liu Y; Chen Y; Wang F; Zhang R; Wang X; Yuan J
Oxid Med Cell Longev; 2022; 2022():1112987. PubMed ID: 35770045
[TBL] [Abstract] [Full Text] [Related]
10. Anticancer activity of D-LAK-120A, an antimicrobial peptide, in non-small cell lung cancer (NSCLC).
Patil SM; Kunda NK
Biochimie; 2022 Oct; 201():7-17. PubMed ID: 35764196
[TBL] [Abstract] [Full Text] [Related]
11. Exploring Liposomes for lung cancer Therapy.
Shahid A; Khan MM; Ahmad U; Haider MF; Ali A
Crit Rev Ther Drug Carrier Syst; 2022; 39(4):1-47. PubMed ID: 35695657
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy of Osimertinib in lung Squamous Cell Carcinoma Patients with
Rekowska A; Rola P; Wójcik-Superczyńska M; Chmielewska I; Krawczyk P; Milanowski J
Curr Oncol; 2022 May; 29(5):3531-3539. PubMed ID: 35621675
[TBL] [Abstract] [Full Text] [Related]
13. Initial treatment of early-stage small-sized non-small cell lung cancer for octogenarians: a population-based study.
Huang W; Deng HY; Xu K; Lin MY; Li P; Yuan C; Zhou Q
Updates Surg; 2022 Aug; 74(4):1461-1470. PubMed ID: 35386041
[TBL] [Abstract] [Full Text] [Related]
14. The Value of Artificial Intelligence Film Reading System Based on Deep Learning in the Diagnosis of Non-Small-Cell lung cancer and the Significance of Efficacy Monitoring: A Retrospective, Clinical, Nonrandomized, Controlled Study.
Chen Y; Tian X; Fan K; Zheng Y; Tian N; Fan K
Comput Math Methods Med; 2022; 2022():2864170. PubMed ID: 35360550
[TBL] [Abstract] [Full Text] [Related]
15. Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
Kaewjanthong P; Sooksai S; Sasano H; Hutvagner G; Bajan S; McGowan E; Boonyaratanakornkit V
PLoS One; 2022; 17(3):e0264717. PubMed ID: 35235599
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of Naples prognostic score in non-small-cell lung cancer patients with brain metastases.
Xuan J; Peng J; Wang S; Cai Y
Future Oncol; 2022 Apr; 18(13):1545-1555. PubMed ID: 35107367
[TBL] [Abstract] [Full Text] [Related]
17. Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer.
Zhang M; Huang C; Zhou H; Liu D; Chen R; Li X; Cheng Y; Gao B; Chen J
Thorac Cancer; 2022 Jan; 13(1):95-106. PubMed ID: 34791810
[TBL] [Abstract] [Full Text] [Related]
18. Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC).
Zhou YJ; Zheng W; Zeng QH; Ye Y; Wang C; Fang C; Liu CJ; Niu L; Wu LM
Hum Genomics; 2021 Apr; 15(1):21. PubMed ID: 33845897
[TBL] [Abstract] [Full Text] [Related]
19. The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges.
Xie S; Wu Z; Qi Y; Wu B; Zhu X
Biomed Pharmacother; 2021 Jun; 138():111450. PubMed ID: 33690088
[TBL] [Abstract] [Full Text] [Related]
20. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract] [Full Text] [Related]
[Next]
